PTC TherapeuticsFRA:BH3 +3.39%51 Days Payable is 114.58 as of Mar. 2026, which is 53% below its 10-year median of 243.63. GuruFocus rates FRA:BH3 with a GF Score™ of 51/100 and a GF Value™ of €31.02. The stock has 9 warning signs investors should review. Among 702 Biotechnology companies, PTC Therapeutics ranks better than 60.4% on this metric.
The historical rank and industry rank for PTC Therapeutics's Days Payable or its related term are showing as below:
FRA:BH3'
s Days Payable Range Over the Past 10 Years
Min: 74.14 Med: 243.63 Max: 860.47
Current: 175.22
During the past 13 years, PTC Therapeutics's highest Days Payable was 860.47. The lowest was 74.14. And the median was 243.63.
FRA:BH3's Days Payable is ranked better than 60.4% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs FRA:BH3: 175.22
PTC Therapeutics's Days Payable
declined
from Mar. 2025 (117.00) to Mar. 2026 (114.58).
It may suggest that PTC Therapeuticsaccelerated paying its suppliers.
PTC Therapeutics Days Payable Related Terms
PTC Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for PTC Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BH3 vs SRRK, COGT, RYTM: Days Payable Comparison
For the Biotechnology subindustry, PTC Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PTC Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTC Therapeutics (FRA:BH3) has a Days Payable of 114.58 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PTC Therapeutics and its competitors. This is 53% below median its historical median of 243.63. Over the past decade, PTC Therapeutics' Days Payable has ranged from 74.14 to 860.47. According to the industry distribution chart, PTC Therapeutics ranks #278 out of 702 companies in the Biotechnology industry, placing it in the top 39.6%.
Is PTC Therapeutics' Days Payable too high?
PTC Therapeutics' current Days Payable of 114.58 is 53% below median its 10-year median of 243.63. Over the past 10 years, this metric has ranged from a low of 74.14 to a high of 860.47. The Biotechnology industry median Days Payable is 113.10. PTC Therapeutics' value of 114.58 is 1.3% above this industry median. Based on the distribution chart, PTC Therapeutics ranks #278 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PTC Therapeutics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Days Payable compare to SRRK and COGT?
According to the Biotechnology industry distribution chart, PTC Therapeutics ranks #278 out of 702 companies for Days Payable. This puts PTC Therapeutics in the upper half of its industry. The industry median Days Payable is 113.10. PTC Therapeutics' value of 114.58 is 1.3% above this benchmark. Historically, PTC Therapeutics' own Days Payable has ranged from 74.14 to 860.47 over the past decade. While the company's 10-year median is 243.63 vs. the industry median of 113.10, PTC Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PTC Therapeutics's current Days Payable of 114.58 is 1.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PTC Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PTC Therapeutics's current Days Payable is 114.58, which is 53% below median its own 10-year median of 243.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Days Payable of 114.58. The stock's GF Value™ is €31.02, compared to a current price of €72.52 — trading 133.8% above its estimated fair value. The current Days Payable is 114.58, which is 53% below median its 10-year median of 243.63 and 1.3% above the Biotechnology industry median of 113.10. PTC Therapeutics' overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Days Payable is 114.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?
Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued.
The current stock price of €72.52 is trading 133.8% above its estimated GF Value™ of €31.02.
Key valuation signals for FRA:BH3:
Days Payable: 114.58 (53% below median its 10-year median of 243.63)
GF Value™: €31.02 vs. price of €72.52 (133.8% above fair value)
Industry Position: 1.3% above the Biotechnology median (#278 of 702)
No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score
Get the complete analysis for FRA:BH3
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BH3 has been successfully added to your 
